Astellas Pharma Gmbh

Hisashi Mihara

Daisuke Suzuki

Norio Seki

Susumu Yamaki

Hiroyoshi Yamada

Kousei Yoshihara

Hiroaki Tanaka

Daisuke Yamashita

Hiroyuki Moritomo

Keizo Sugasawa

Kenji Negoro

Takashi Sugane

Hajime Takamatsu

Takafumi Shimizu

Yasuhiro Yonetoku

Kyoichi Maeno

Taisuke Takahashi

Norio Asai

Takuya Makino

Michinori Akaiwa

Naomi Hosogai

Daisuke Tanabe

Kazuhiko Osoda

Hideyoshi Fuji

To provide a compound which can be used as an MCreceptor agonist. The present inventors have investigated MCreceptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MCreceptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Piperazine derivative

A compound which is useful as an active ingredient for a pharmaceutical composition for treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. The present inventors have found that a 2-aminothiazole derivative has an excellent muscarinic Mreceptor-positive allosteric modulator activity and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic Mreceptor, thereby completing the present invention. 2-aminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic Mreceptor, for example voiding dysfunction such as underactive bladder.

2-aminothiazole derivative or salt thereof

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

Guanidine compound

Growing community of inventors

Chuo-ku, Japan

Hisashi Mihara